



Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

16.12.2015

Dear Sir,

Sub : Information Notice.
Ref : Scrip Code BALPH

With reference to the above, we are submitting to the exchange the enclosed Information Notice on the Anti Dumping duty imposed by Ministry of Finance, Government of India against dumping of the bulk drug 'Gliclazide' into Indian market by China .

Please take this information notice on record and disseminate the same to the market for the benefit of our share holders and Indian pharma industry.

Thanking You.

For Bal Pharma Limited

For BAL PHARMA LIMITED

Sanjay Agarwal
SANJAY KUMAR AGARWAL
Authorised Signatory.
Secretary



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820



Bal Pharma Limited

INFORMATION NOTICE

Sub : Government imposes Anti Dumping Duty on Gliclazide.

With reference to the above , We are pleased to inform exchanges and all our share holders that Government of India , Ministry of Finance vide its notification # 59/2015 – Customs (ADD) dated 8th December 2015 has considered the Anti Dumping application filed by the Company against dumping of the bulk drug 'Gliclazide' into Indian Market by Peoples Republic of China with unreasonable price advance and has imposed definitive anti-dumping duty on the import of 'Gliclazide' into Indian Market.

The Ministry of Finance has considered the following ill effects of dumping before imposing anti-dumping duty.

- a) Gliclazide have been exported to India from Peoples Republic of China below its normal value.
- b) The domestic industry has suffered material injury due to this dumping.
- c) The injury has been caused cumulatively due to imports from China.

This is a very welcome development for Bal Pharma Limited which is the largest producer of the bulk drug 'Gliclazide' in India, as Gliclazide contributes substantially to the Companies revenues. Bal Pharma supplies 'Gliclazide' to both domestic and export markets and enjoys a very decent market share in both the markets. The Company manufactures Gliclazide at its manufacturing facility located in Bangalore and the therapeutic nature the drug is anti diabetic /Hypoglycaemic.

With this anti dumping notification , the Company will have a distinctive advantage to consolidate its market share in domestic and international markets and also will significantly improve its revenues if it can meet the demand of the Gliclazide sans supplies from China.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820

About Bal Pharma Ltd: Bal Pharma Ltd is an widely held public limited company having its manufacturing presence across India and marketing network across the globe. The Company specializes in the manufacture of Formulations, Active pharma Ingredients (API's) and intermediates exclusively developed by its own state of the art R& D center at Bangalore, with various national and international accreditation's. Bal Pharma products are sold in more than 80 countries across the globe and have high value niche products like Gliclazide and Ebastine in its product portfolio.

For additional Information, please contact Mr.Venu Madhava Reddy on Phone : 080 41379538
Fax : 080 22354057 & e-mail :secretarial@balpharma.com.